Clinical Trial Update: Effect of Escalating Doses of a Novel Viscous Polysaccharide on Postprandial Glycemia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluated escalating doses of a novel viscous polysaccharide for reducing postprandial blood glucose, and the studies have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Glucose Tolerance
• Type 2 Diabetes Mellitus

Drugs mentioned

• Novel viscous polysaccharide

Snippet

Sponsor: Glycemic Index Laboratories, Inc | Conditions: Blood Glucose, Postprandial | Phase 2, Phase 3 | Status: COMPLETED